Academic article

• Lydia D. Boyle; Brice Sylvain Daniel Marty; Kristoffer Haugarvoll et al. (2026). Use of sensing technologies to assess sleep quality and physical activity levels in nursing home residents with dementia taking nightly psychotropic drugs for sleep disturbance: a cross-sectional study. (external link)
• Lydia Boyle; Monica Patrascu; Bettina Elisabeth Franziska Husebø et al. (2025). Use of Digital Biomarkers from Sensing Technologies to Explore the Relationship Between Daytime Activity Levels and Sleep Quality in Nursing Home Residents with Dementia: A Proof-of-Concept Study. (external link)
• Kristoffer Haugarvoll; R Rademakers; JM Kachergus et al. (2008). Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. (external link)
• Lydia Boyle; Brice Sylvain Daniel Marty; Kristoffer Haugarvoll et al. (2025). Selecting a smartwatch for trials involving older adults with neurodegenerative diseases: A researcher's framework to avoid hidden pitfalls. (external link)
• Geir Olve Skeie; Bente Müller; Kristoffer Haugarvoll et al. (2013). Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study. (external link)
• Irene Hana Flønes; Pawel Szymon Sztromwasser; Kristoffer Haugarvoll et al. (2016). Novel SLC19A3 promoter deletion and allelic silencing in biotin-thiamine-responsive basal ganglia encephalopathy. (external link)
• Kristoffer Haugarvoll; Laurence Bindoff (2011). A novel compound heterozygous tyrosine hydroxylase mutation (p.R441P) with complex phenotype. (external link)
• Christian Dölle; Irene Hana Flønes; Gonzalo Sanchez Nido et al. (2016). Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease. (external link)
• Kristoffer Haugarvoll; Charalampos Tzoulis; Gia Tuong Thi Tran et al. (2014). Myoclonus-dystonia and epilepsy in a family with a novel epsilon-sarcoglycan mutation. (external link)
• Johannes Jernqvist Gaare; Gonzalo Sanchez Nido; Pawel Szymon Sztromwasser et al. (2018). Rare genetic variation in mitochondrial pathways influences the risk for parkinson's disease. (external link)
• Kristoffer Haugarvoll; Mathias Toft; L Skipper et al. (2009). Fine-mapping and candidate gene investigation within the PARK 10 locus. (external link)
• Charalampos Tzoulis; Thomas Schwarzlmüller; Martin Biermann et al. (2016). Mitochondrial DNA homeostasis is essential for nigrostriatal integrity. (external link)
• Brage Brakedal; Christian Dölle; Frank Riemer et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. (external link)
• Yasaman Pakdaman; Monica Sanchez Guixe; Rune Kleppe et al. (2017). In vitro characterization of six STUB1 variants in spinocerebellar ataxia 16 reveals altered structural properties for the encoded CHIP proteins. (external link)
• Charalampos Tzoulis; Gia Tuong Thi Tran; Thomas Schwarzlmüller et al. (2013). Severe nigrostriatal degeneration without clinical parkinsonism in patients with polymerase gamma mutations. (external link)
• Novin Balafkan; Charalampos Tzoulis; Bernd Muller et al. (2012). Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population. (external link)
• Kristoffer Haugarvoll; ZK Wszolek; M Hutton (2007). The genetics of frontotemporal dementia. (external link)
• Johannes Jernqvist Gaare; Gonzalo Sanchez Nido; Christian Dölle et al. (2020). Meta-analysis of whole-exome sequencing data from two independent cohorts finds no evidence for rare variant enrichment in Parkinson disease associated loci. (external link)
• Mathias Toft; IF Mata; OA Ross et al. (2007). Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. (external link)
• OA Ross; MG Heckman; AI Soto et al. (2008). Dopamine beta-hydroxylase-1021C > T association and Parkinson's disease. (external link)
• Kristoffer Haugarvoll; Mathias Toft; OA Ross et al. (2007). ELAVL4, PARK10, and the Celts. (external link)
• Jan Aasly; C Vilarino-Guell; JC Dachsel et al. (2010). Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. (external link)
• OA Ross; Kristoffer Haugarvoll; JT Stone et al. (2007). Lack of evidence for association of Parkin promoter polymorphism (PRKN-258) with increased risk of Parkinson's disease. (external link)
• C Wider; SJ Lincoln; MG Heckman et al. (2009). Phactr2 and Parkinson's disease. (external link)
• Christina Heidemann Sundal; Matt C. Baker; Virginija Danylaité Karrenbauer et al. (2015). Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. (external link)
• Geir Olve Skeie; Bernd Mueller; Kristoffer Haugarvoll et al. (2010). Differential Effect of Environmental Risk Factors on Postural Instability Gait Difficulties and Tremor Dominant Parkinson's Disease. (external link)
• Kristoffer Haugarvoll; Stefan Johansson; Carlos E. Rodriguez et al. (2017). GBA2 mutations cause a Marinesco-Sjogren-like syndrome: Genetic and biochemical studies. (external link)
• Bergithe Eikeland Oftedal; Alexander Hellesen; Martina Moter Erichsen et al. (2015). Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. (external link)
• Mathias Toft; Kristoffer Haugarvoll; OA Ross et al. (2007). LRRK2 and Parkinson's disease in Norway. (external link)
• Johannes Jernqvist Gaare; Christian Dölle; Brage Brakedal et al. (2023). Nicotinamide riboside supplementation is not associated with altered methylation homeostasis in Parkinson's disease. (external link)
• Simon Ulvenes Kverneng; Kjersti Eline Stige; Haakon Berven et al. (2025). Mitochondrial complex I deficiency occurs in skeletal muscle of a subgroup of individuals with Parkinson’s disease. (external link)
• Gonzalo Sanchez Nido; Fiona Dick; Lilah Toker et al. (2020). Common gene expression signatures in Parkinson’s disease are driven by changes in cell composition. (external link)
• Brage Brakedal; Charalampos Tzoulis; Ole-Bjørn Tysnes et al. (2021). NSAID use is not associated with Parkinson's disease incidence: A Norwegian Prescription Database study. (external link)
• Brage Brakedal; Irene Hana Flønes; Simone B. C. Frizell Reiter et al. (2017). Glitazone use associated with reduced risk of Parkinson's disease. (external link)
• C Wider; JC Dachsel; AI Soto et al. (2009). FGF20 and Parkinson's Disease: No Evidence of Association or Pathogenicity via alpha-Synuclein Expression. (external link)
• Haakon Berven; Simon Ulvenes Kverneng; Erika Sheard et al. (2023). NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease. (external link)
• Irit Titlestad; Kristoffer Haugarvoll; Stein-Erik Hafstad Solvang et al. (2024). Delirium is frequently underdiagnosed among older hospitalised patients despite available information in hospital medical records. (external link)
• Omar Hikmat; Charalampos Tzoulis; Wui K. Chong et al. (2017). The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. (external link)
• Gonzalo Sanchez Nido; Christian Dölle; Irene Hana Flønes et al. (2018). Ultradeep mapping of neuronal mitochondrial deletions in Parkinson's disease. (external link)
• Irene Hana Flønes; Erika Fernandez-Vizarra; Maria Lykouri et al. (2017). Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. (external link)
• Omar Hikmat; Charalampos Tzoulis; Claus Klingenberg et al. (2017). The presence of anaemia negatively influences survival in patients with POLG disease. (external link)
• Irene Hana Flønes; Kristoffer Haugarvoll; Christina Heidemann Sundal et al. (2015). En kvinne i 70-årene med langvarige gangvansker. (external link)
• Kristoffer Haugarvoll; Stefan Johansson; Charalampos Tzoulis et al. (2013). MRI characterisation of adult onset alpha-methylacyl-coA racemase deficiency diagnosed by exome sequencing. (external link)
• Lilah Toker; Gia T. Tran; Janani Sundaresan et al. (2021). Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain. (external link)
• Kristoffer Haugarvoll; Mathias Toft; OA Ross et al. (2007). Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway. (external link)
• Ole Tveiten; Geir Olve Skeie; Kristoffer Haugarvoll et al. (2013). Treatment in early Parkinson's disease: the Norwegian ParkWest study. (external link)
• Hege Vefring; Kristoffer Haugarvoll; Ole-Bjørn Tysnes et al. (2010). The role of APOE alleles in incident Parkinson's disease. The Norwegian ParkWest Study. (external link)
• Brage Brakedal; Lilah Toker; Kristoffer Haugarvoll et al. (2022). A nationwide study of the incidence, prevalence and mortality of Parkinson’s disease in the Norwegian population. (external link)
• Bernd Mueller; J. Assmus; J. P. Larsen et al. (2013). Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. (external link)
• Charalompos Tzoulis; Tetyana Zayats; Per Knappskog et al. (2015). HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia. (external link)

Conference abstract

• Lydia Boyle; Bettina Elisabeth Franziska Husebø; Brice Sylvain Daniel Marty et al. (2024). Digital phenotyping for changes in activity at the end of life in people with dementia. (external link)

Academic literature review

• Lydia Boyle; Lionel Giriteka; Brice Sylvain Daniel Marty et al. (2025). Activity and Behavioral Recognition Using Sensing Technology in Persons with Parkinson’s Disease or Dementia: An Umbrella Review of the Literature. (external link)
• Kjersti Eline Stige; Simon Ulvenes Kverneng; Soumya Sharma et al. (2024). The STRAT-PARK cohort: A personalized initiative to stratify Parkinson's disease. (external link)
• Omar Hikmat; Tom Eichele; Charalampos Tzoulis et al. (2017). Understanding the epilepsy in POLG related disease. (external link)

Doctoral thesis (PhD)

• Irene Hana Flønes; Charalampos Tzoulis; Christian Dölle et al. (2019). Mitochondrial mechanisms in neurodegeneration. (external link)

Letter to the editor

• MJ Farrer; K Haugarvoll; OA Ross et al. (2006). Genomewide association, Parkinson disease, and PARK10. (external link)
• Kristoffer Haugarvoll; Laurence Bindoff; Charalampos Tzoulis (2016). Nigrostriatal denervation sine parkinsonism. (external link)
• C Vilarino-Guell; OA Ross; AI Soto et al. (2009). Reported Mutations in GIGYF2 are not a Common Cause of Parkinson's Disease. (external link)
• Brage Brakedal; Kristoffer Haugarvoll; Charalampos Tzoulis (2017). Simvastatin is associated with decreased risk of Parkinson disease. (external link)
• Johannes Jernqvist Gaare; Gonzalo Sanchez Nido; Pawel Szymon Sztromwasser et al. (2018). No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson's disease. (external link)

Journal corrigendum

• Omar Hikmat; Charalampos Tzoulis; Claus Klingenberg et al. (2017). Erratum to: The presence of anaemia negatively influences survival in patients with POLG disease (Journal of Inherited Metabolic Disease, (2017), 40, 6, (861-866), 10.1007/s10545-017-0084-9). (external link)

See a complete overview of publications in NVA.

Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/?term=haugarvoll+k